Annexon (NASDAQ:ANNX) Given Overweight Rating at Cantor Fitzgerald

Cantor Fitzgerald reaffirmed their overweight rating on shares of Annexon (NASDAQ:ANNX) in a report released on Wednesday, Benzinga reports.

Other analysts have also issued reports about the company. HC Wainwright reaffirmed a buy rating and set a $30.00 target price on shares of Annexon in a research report on Wednesday, March 27th. JPMorgan Chase & Co. lifted their target price on Annexon from $11.00 to $13.00 and gave the stock an overweight rating in a research report on Monday, April 1st. Bank of America lifted their target price on Annexon from $7.00 to $10.00 and gave the stock a buy rating in a research report on Thursday, March 28th. Needham & Company LLC reissued a buy rating and issued a $16.00 price objective on shares of Annexon in a report on Thursday, April 11th. Finally, Wells Fargo & Company boosted their price objective on Annexon from $11.00 to $12.00 and gave the company an overweight rating in a report on Wednesday, March 27th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has a consensus rating of Buy and a consensus price target of $14.43.

Annexon Price Performance

Shares of ANNX opened at $4.70 on Wednesday. The stock’s 50-day moving average is $5.67 and its two-hundred day moving average is $4.17. The stock has a market cap of $423.14 million, a PE ratio of -2.64 and a beta of 1.14. Annexon has a 12 month low of $1.57 and a 12 month high of $8.40.

Annexon (NASDAQ:ANNX) last issued its quarterly earnings data on Tuesday, March 26th. The company reported ($0.36) EPS for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.09. On average, research analysts anticipate that Annexon will post -1.36 earnings per share for the current year.

Insider Activity at Annexon

In other news, CEO Douglas Love sold 5,782 shares of the company’s stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $5.54, for a total transaction of $32,032.28. Following the completion of the transaction, the chief executive officer now directly owns 196,121 shares of the company’s stock, valued at $1,086,510.34. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders sold a total of 8,940 shares of company stock valued at $49,514 over the last three months. 19.11% of the stock is owned by insiders.

Hedge Funds Weigh In On Annexon

Institutional investors have recently made changes to their positions in the stock. Kennedy Capital Management LLC bought a new position in shares of Annexon during the third quarter valued at approximately $2,306,000. SG Americas Securities LLC boosted its position in shares of Annexon by 14.1% during the fourth quarter. SG Americas Securities LLC now owns 25,335 shares of the company’s stock worth $115,000 after buying an additional 3,123 shares during the period. Sectoral Asset Management Inc. boosted its position in shares of Annexon by 33.2% during the third quarter. Sectoral Asset Management Inc. now owns 898,785 shares of the company’s stock worth $2,121,000 after buying an additional 224,156 shares during the period. Silverarc Capital Management LLC boosted its position in shares of Annexon by 2.5% during the third quarter. Silverarc Capital Management LLC now owns 399,716 shares of the company’s stock worth $943,000 after buying an additional 9,805 shares during the period. Finally, Forefront Analytics LLC boosted its position in shares of Annexon by 18.3% during the third quarter. Forefront Analytics LLC now owns 31,680 shares of the company’s stock worth $75,000 after buying an additional 4,890 shares during the period.

About Annexon

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.